ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Other Financing Activities

Financing cash flows not reported separately.

ProQR Therapeutics N.V.NASDAQ: PRQR

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities turns negative

Q1 FY2026 other financing activities was -€5K, compared with €67K a year earlier. Trailing-twelve-month other financing activities was €5.85K. Over 3 fiscal years it compounded at +30.3% a year.

Context

  • Other financing activities amounted to 0.5% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other financing activities holds near -€5K or moves back toward the trailing-twelve-month quarterly average of €1.46K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€5K-146.1% QoQ
Last fiscal yearDec 2025
€75.19K-66.3% YoY
LTMMar 2026
€5.85K-100.0% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-107.5%——
1 year-66.3%——
3-year CAGR+30.3%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

EUR · from the cash flow

Latest · FY2025
75.19K EUR
Year-over-year change
-66.3%
4-year CAGR
-52.8%

Other Financing Activities vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the 5th highest of 11, against a peer median of -100.0%.
  • Other financing activities amounts to 0.0% of revenue for PRQR, versus a peer median of 6.3%.
PRQR Competitors
Other Financing Activities for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$14.23M USD-515.6%—31.4%
ZURAZura Bio LimitedLTM Mar 2026$7.37M USD-106.7%+37.5%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$3.56M USD-43.4%——
EDITEditas Medicine, Inc.LTM Mar 2026$2.89M USD+200.7%—7.5%
IMMPImmutep LimitedFY2025A$254.46K AUD-94.7%-52.8%5.0%
MREOMereo BioPharma Group plcLTM Mar 2026$134K USD-100.3%—26.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026€5.85K EUR-100.0%+30.3%0.0%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 USD-100.0%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%-83.9%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$0 USD+100.0%—0.0%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding PRQR) —-100.0%-52.8%6.3%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(60.8M)(64.2M)(27.74M)(27.76M)(40.52M)
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
Deferred Income Tax117K96K(78K)(197K)0
Stock-Based Compensation6.22M2.87M3.11M2.54M0
Change in Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Other Non-Cash Items1.11M(4.8M)(5.21M)(474K)3.94M
Operating Cash Flow(26.01M)(68.51M)21.55M(36.39M)(50.71M)
Capital Expenditures(484K)(708K)(1.37M)(1.42M)(979.75K)
Acquisitions (Net)00000
Purchases of Investments000(17M)0
Sales of Investments00017M0
Other Investing Activities59K6K5.65M(2.66M)0
Investing Cash Flow(425K)(702K)4.28M(4.07M)(979.74K)
Debt Repayment26.84M(45.05M)(2.63M)(1.58M)(1.91M)
Common Stock Issued108.48M14.12M071.64M66.28K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M34K354K223K75.19K
Financing Cash Flow136.83M(30.89M)(2.28M)70.28M(1.76M)
Effect of Forex Changes1.29M7.35M599K673K14.15M
Net Change in Cash111.69M(92.75M)24.15M30.48M(39.3M)
Free Cash Flow(26.5M)(69.22M)20.18M(37.81M)(51.69M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.